Here's why the Volpara (ASX:VHT) share price is up 6% today

The Volpara (ASX: VHT) share price is gaining today after the company released its quarterly results. Let's take a look.

| More on:
Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Volpara Health Technologies Ltd (ASX: VHT) shares are gaining today after the company released its quarterly results. At the time of writing, the Volpara share price is up 6.25%, trading at $1.36 apiece.

Volpara is a health technology software company, providing an integrated breast care platform to deliver personalised breast care. Let's take a closer look at the New Zealand-based company's latest results.

Fourth-quarter results

The company released its results for the fourth quarter of the 2021 financial year this morning, garnering a positive reaction from investors.

Good news from the company included a record cash income from customer receipts, equalling NZ$5.4 million. That figure represents a 15% increase compared to the fourth quarter of 2020.

The company's subscription-based receipts were also up, raking in NS$18.3 million – a 39% year on year increase.

Volpara also announced increases in its unaudited cash receipts for the full year ending 31 March 2021, up 20% year on year.

Its net operating cash outflow was better than the company's internal forecasting, and it ended the quarter with $32.2 million cash in the bank.

Volpara's earnings before interest, tax, depreciation and amortisation (EBITDA) came in at a loss of NZ$3,432,000.

Today is the second time Volpara's share price has reacted positively to its results for this quarter. On 20 April, the Volpara released a business update on the fourth quarter, which also saw its share price rise.

Unfortunately, its gains didn't hold that day, and the Volpara share price ended the session trading 4.2% lower than the previous close.

Commentary from management

Volpara CEO Dr Ralph Highnam commented on the results, saying:

Our achievements in [the 2021 financial year] are a powerful endorsement of what we stand for as a company and the strength and commitment of our industry to keep saving families from cancer, no matter what else is going on.

We look forward to continuing to accelerate out of COVID-19 in [the 2022 financial year].

Volpara share price snapshot

Currently, the Volpara share price is down 3% year to date, although it's up 8% over the last 12 months.

The company has a market capitalisation of around $321 million, with approximately 251 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends VOLPARA FPO NZ. The Motley Fool Australia has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Growth Shares

Up more than 800% in a year. Why this ASX medical tech stock just hit an all-time high

4DMedical shares have surged over 800% as US hospital adoption and FDA clearance drive momentum.

Read more »

A retiree relaxing in the pool and giving a thumbs up.
Healthcare Shares

1 ASX dividend stock down 36% I'd buy right now

This business looks like it’s priced too cheaply.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Healthcare Shares

Top broker says this ASX small-cap healthcare stock could be set to double

This company is making significant clinical and commercial progress .

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 quality ASX healthcare shares worth buying now

Brokers think the tide is turning for these battling medical heavyweights.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Early success in battling Crohn's Disease has sent this ASX biotech's shares soaring

The early-stage results have been described as outstanding.

Read more »